Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants

Vandana Singh
·1 min read
3

  • Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial.

  • The new results demonstrate a broad neutralizing antibody response against omicron variants of concern, including BA.5, lasting up to at least six months after administering a low-dose (5 mcg) ARCT-154 booster.

  • “Our next generation low-dose self-amplifying (STARR™) mRNA technology continues to differentiate itself from conventional mRNA vaccine technology,” said Joseph Payne, President & CEO.

  • “Further validation of the breadth and duration for the immune responses to ARCT-154 are planned in upcoming pivotal clinical trial activities,” he added.

  • Related: Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial.

  • After one month and three months, neutralizing antibody responses to Omicron BA.5 were 33- and 20-fold elevated over pre-boost responses, respectively.

  • After six months, neutralizing antibody responses to omicron BA.1, BA.2, and BA.5 ranged from 22-52 fold, 25-55 fold and 9-24 fold elevated over pre-boost responses, respectively.

  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including omicron BA.5, for at least six months after vaccination.

  • Price Action: ARCT shares are down 6.79% at $19.05 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.